Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8161 to 8175 of 9007 results

  1. Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)

    This guidance has been updated and replaced by NICE HealthTech guidance 668.

    Withdrawn guidance

  2. Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

    In development Reference number: GID-TA10467 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

    Discontinued Reference number: GID-TA10522

    Technology appraisal guidance
    Discontinued

  4. Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

    In development Reference number: GID-TA10592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]

    Discontinued Reference number: GID-TA10525

    Technology appraisal guidance
    Discontinued

  6. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued Reference number: GID-TA10316

    Technology appraisal guidance
    Discontinued

  7. Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

    In development Reference number: GID-TA10800 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued Reference number: GID-TAG482

    Technology appraisal guidance
    Discontinued

  9. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

    Technology appraisal guidance
    Discontinued

  10. Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

    Discontinued Reference number: GID-TA10105

    Technology appraisal guidance
    Discontinued

  11. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Discontinued Reference number: GID-TA11486

    Technology appraisal guidance
    Discontinued

  12. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Inotersen for treating hereditary transthyretin amyloidosis (HST9)

    NICE has withdrawn this guidance. Sobi will stop marketing inotersen (Tegsedi) because its no longer available in the UK. Healthcare professionals should discuss alternative treatment options with people currently having inotersen.

    Withdrawn guidance

  14. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    Discontinued Reference number: GID-TA10597

    Technology appraisal guidance
    Discontinued

  15. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued Reference number: GID-TA10596

    Technology appraisal guidance
    Discontinued